Ostarine

Ostarine, also known as Enbosarm or MK-2866, is a selective androgen receptor modulator (SARM) that has been shown to be effective in helping people lose weight and build muscle mass. Ostarine works by binding to the androgen receptors in the body, which can help reduce body fat and increase muscle mass. It is non-toxic and has few side effects, making it a safe choice for those looking for an edge in the gym.

(2S)-3-(4-Cyanophenoxy-2,3,5,6-d4)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide is a metabolites of selective androgen receptor modulators (SARM).

Ostarine is a non-steroidal agent with anabolic activity. Selective androgen receptor modulator (SARM) GTx-024 is designed to work like testosterone, thus promoting and/or maintaining libido, fertility, prostate growth, and muscle growth and strength. Mimicking testosterone's action, this agent may increase lean body mass, thereby ameliorating muscle wasting in the hypermetabolic state of cancer cachexia.
Ostarine has been used in trials studying the treatment of Stress Urinary Incontinence and Triple Negative Breast Cancer.

Ostarine is a selective androgen receptor modulator (SARM) with Ki of 3.8 nM. Plasma concentration of ostarine declines in a biexponential manner after intravenous administration with terminal half-live of 6.0 hours. In vivo, ostarine significantly stimulates the growth of prostate, seminal vesicles, and levator ani muscle in castrated rats. Ostarine restores the weights of the prostate to 39.2%, of that observed in the intact control. The weight of seminal vesicle is also restored by ostarine to 78.8%, respectively, of that observed in the intact control. Ostarine stimulates the growth of levator ani muscle to a greater extent than androgenic organs, to 141.9%.

Ostarine is nonsteroidal selective androgen receptor modulator (SARM) used in the treatment of osteoporosis and muscle wasting in animal models. A potential compound for the treatment of hypoactive sexual desire disorder.

A kind of SARM is known as Ostarine MK-2866. It is generally prescribed to prevent and treat muscle weakness. These health issues may be genetic in nature due to HIV/AIDS or other ailments. There are studies in place that suggest the medication could soon be recommended as part of hormone replacement treatment (HRT). SARMS create anabolic selective activity in a variety of androgen receptors. There isn't any androgenic action, however, for non-skeletal muscle tissues as there is when you use testosterone or anabolic steroids.

Ostarine is an orally bioavailable, nonsteroidal SARM that was developed by Gtx, Inc. in the late 1990s primarily for the treatment of muscle wasting and osteoporosis.

Common low-grade side effects included headache, nausea, fatigue, and back pain. Other observed effects were transient elevation in the alanine transaminase (ALT), reductions in high density lipoprotein (HDL), blood glucose, insulin, and insulin resistance. The side effects of decreased testosterone include reduced sex drive, infertility, muscle weakness, loss of bone density, weight gain accompanied by increased body fat, insomnia, and depression.

[1] NATALIA LECIEJEWSKA . Sex-specific cytotoxicity of ostarine in cardiomyocytes[J]. Molecular and Cellular Endocrinology, 2023, 577: Article 112037. DOI:10.1016/j.mce.2023.112037.
[2] HARJOT BEDI. Drug-Induced Liver Injury From Enobosarm (Ostarine), a Selective Androgen Receptor Modulator.[J]. ACG Case Reports Journal, 2021: e00518. DOI:10.14309/crj.0000000000000518.
[3] PJ R, D H, JC C, et al. Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model.[J]. Front Endocrinol (Lausanne), 2020, 11: 556581.
[4] JAMES T. DALTON. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial[J]. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2 3: 153-161. DOI:10.1007/s13539-011-0034-6.
[5] ADRIAN S DOBS. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.[J]. Lancet Oncology, 2013, 14 4: 335-345. DOI:10.1016/S1470-2045(13)70055-X.
[6] JEFFREY CRAWFORD. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).[J]. Current Oncology Reports, 2016, 18 6: 37. DOI:10.1007/s11912-016-0522-0.
[7] ALVARO MORALES. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline.[J]. Canadian Medical Association journal, 2015, 187 18: 1369-1377. DOI:10.1503/cmaj.150033.
[8] Watts D. Ostarine Reviews: shocking results & information about MK2866. SECEC. https://secec.org/ostarine-mk2866/. Accessed May 18, 2020.